Patent protection is of critical importance to the emerging psychedelic drug industry. With two types of drug patents and much additional patentable IP, there is much for investors to learn.
Optimi Health Clears Final Base Shelf Prospectus
Optimi Health announces it has filed a Final Shelf Prospectus.
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
Mydecine signs a 5-year research agreement with Johns Hopkins University, with an initial focus on smoking cessation.
Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results
Field Trip Health Ltd., a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021.
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
MindMed announces joining a research consortium, the Patient-Reported Outcome Consortium, to assist in its mission to advance medical innovation.
Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion
Cybin announces the filing of a non-provisional patent application, the company's 14th patent application.
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
MindMed reports a Q2 2021 loss of $36 million. Current cash on hand of $157 million.
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
ATAI's newest research partner, Revixia Life Sciences, is seeking to treat depression and substance abuse with Salvinorin A, a lesser-known psychedelic used by indigenous peoples.
Is Access To Psychedelic Medicine The Largest Human Rights Issue Today?
The Mental Health Crisis is now a mental health pandemic. Is access to psychedelic medicine the world's largest human rights issue?
Wesana Health Commences Functional Animal Study for Treatment of Traumatic Brain Injury
Wesana Health announces the commencement of pre-clinical psychedelics research for Traumatic Brain Injury.
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
Compass Pathways reports a Q2 loss of $17.5 million and announces raising $154.8 million in a new financing in May.
Psychedelic Medicine vs. Conventional Mental Health Therapies: Cures vs. Crutches
Two billion people have treatable mental health disorders. Where existing therapies are merely inadequate crutches, psychedelic drugs can produce cures.
